medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2020-8-82-87medsovet-5683Research ArticleНЕЙРОДЕГЕНЕРАТИВНЫЕ ЗАБОЛЕВАНИЯNEURODEGENERATIVE DISEASESОбзор терапевтического потенциала Mucuna pruriens L. при болезни ПаркинсонаReview of Mucuna pruriens L. therapeutic potential for Parkinson’s diseasehttps://orcid.org/0000-0003-0556-0552ПановаА. С.PanovaA. S.

Панова Анастасия Сергеевна, экстерн

630126, Россия, Новосибирск, ул. Вилюйская, д. 28

Anastasia S. Panova, external student

28, Vilyuiskaya St., Novosibirsk, 630126, Russia

passad.nsk@gmail.comhttps://orcid.org/0000-0002-2126-8984ДергачёвД. С.DergachevD. S.

Дергачёв Дмитрий Сергеевич, генеральный директор

194165, Россия, Санкт-Петербург, пр-т Энгельса, д. 27, литера ж

Dmitrii S. Dergachev, general director

27, Engels Ave., St. Petersburg, 194165, Russia

angel_a_angel@icloud.comhttps://orcid.org/0000-0001-8633-1254СуботяловМ. А.SubotyalovM. A.

Суботялов Михаил Альбертович, д.м.н., профессор кафедры анатомии, физиологии и безопасности жизнедеятельности

630126, Россия, Новосибирск, ул. Вилюйская, д. 28

Mikhail A. Subotyalov, Dr. of Sci. (Med), professor of the Department of Anatomy, Physiology and Life Safety

28, Vilyuiskaya St., Novosibirsk, 630126, Russia

subotyalov@yandex.ruhttps://orcid.org/0000-0002-3098-1060ДергачёвВ. Д.DergachevV. D.

Дергачёв Владимир Дмитриевич, ординатор

192019, Россия, Санкт-Петербург, ул. Бехтерева, д. 3

Vladimir D. Dergachev, resident

3, Bekhterev St., St. Petersburg, 192019, Russia

archegurrez@yandex.comНовосибирский государственный педагогический университетРоссияNovosibirsk State Pedagogical UniversityRussian FederationМедицинские СистемыРоссияMedical SystemsRussian FederationНациональный медицинский исследовательский центр психиатрии и неврологии им. В.М. БехтереваРоссияV.M. Bekhterev National Research Medical Center for Psychiatry and NeurologyRussian Federation202014072020088287Copyright © Панова А.С., Дергачёв Д.С., Суботялов М.А., Дергачёв В.Д., 20202020Панова А.С., Дергачёв Д.С., Суботялов М.А., Дергачёв В.Д.Panova A.S., Dergachev D.S., Subotyalov M.A., Dergachev V.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/5683

Болезнь Паркинсона – это многофакторное расстройство нервной системы, основными характеристиками которого являются прогрессирующая дегенерация дофаминергических нейронов в nigra pars compacta нигростриарного тракта и после- дующий дефицит нейротрансмиттера дофамина в областях мозга, приводящие к потере моторной функции, появлению немоторных симптомов, ригидности, брадикинезии или акинезии, моторного блока, снижению когнитивных функций. Болезнь Паркинсона широко распространена во всем мире и не имеет однозначного лечения в современной медицине, за исключением паллиативного назначения антихолинергических препаратов вместе с леводопой и ингибитором ДОФА- декарбоксилазы. Хотя дофаминергическая терапия является стандартом для лечения двигательной инвалидности, связанной с болезнью Паркинсона, она не справляется со всеми аспектами заболевания. По этой причине все большее число пациентов ищут более целостный подход в лечении данного заболевания. Mucuna pruriens L. – однолетнее самоопыляющееся бобовое растение, может рассматриваться в качестве потенциальной комплементарной терапии для пациентов с болезнью Паркинсона, так как является чрезвычайно богатым источником леводопы. Многочисленные исследования показали, что экстракты Mucuna pruriens восстанавливают биохимические и поведенческие отклонения у животных с экспериментальной моделью болезни Паркинсона, а также демонстрируют антиоксидантную активность. Клинические эффекты Mucuna pruriens высокой дозы аналогичны леводопе, но с более благоприятным профилем переносимости. Если долгосрочное применение Mucuna pruriens окажется безопасным и эффективным в контролируемых клинических испытаниях, это может стать устойчивой комплементарной терапией для лечения болезни Паркинсона, особенно в странах с низким уровнем дохода.

Parkinson’s disease is a multifactorial disorder of the nervous system, the main features of which are progressive degeneration of dopaminergic neurons in the nigra pars compacta nigrostriatal tract and subsequent deficiency of the neurotransmitter dopamine in the areas of the brain, leading to the loss of motor function, the emergence of non-motor symptoms, rigidity, akinesia or bradykinesia, motor block, and decline in cognitive functions. Parkinson’s disease has high prevalence throughout the world, and has no curative treatment in modern medicine. The available drugs such as anticholinergics, levodopa and a DOPA-decarboxylase inhibitor provide symptomatic relief only. Although dopaminergic therapy is the standard treatment of motor disabilities associated with Parkinson’s disease, it does not managed all the aspects of the disease. For this reason, the increasing numbers of patients are looking for more holistic approach to the treatment of this disease. Mucuna pruriens L. – an annual self-pollinating legume plant, can be considered as a potential complementary therapy for patients with Parkinson’s disease, as it is an extremely rich source of levodopa. Numerous studies have shown that Mucuna pruriens extracts restore biochemical and behavioral abnormalities in animals with the experimental model of Parkinson’s disease. The plant also demonstrates some antioxidant activity. The clinical effects of high-dose Mucuna pruriens are similar to levodopa, but have a more favorable tolerance profile. If long-term use of Mucuna pruriens proves safe and effective in controlled clinical trials, it could become a sustainable complementary therapy for the treatment of Parkinson’s disease, especially in low-income countries.

болезнь ПаркинсонаMucuna pruriensлеводопаАюрведафитотерапияParkinson diseaseMucuna pruriensLevodopaAurvedaphytotherapyReferencesAmro M.S., Teoh S.L., Norzana A.G., Srijit D. The potential role of herbal products in the treatment of Parkinson’s disease. La Clinica terapeutica. 2018;169(1):e23–e33. Available at: http://www.clinicaterapeutica.it/ojs/index.php/ClinicaTerapeutica/article/view/126.Amro M.S., Teoh S.L., Norzana A.G., Srijit D. The potential role of herbal products in the treatment of Parkinson’s disease. La Clinica terapeutica. 2018;169(1):e23–e33. Available at: http://www.clinicaterapeutica.it/ojs/index.php/ClinicaTerapeutica/article/view/126.Banjari I., Marček T., Tomić S., Waisundara V.Y. Forestalling the Epidemics of Parkinson’s Disease Through Plant-Based Remedies. Front Nutr. 2018;5:95. doi: 10.3389/fnut.2018.00095.Banjari I., Marček T., Tomić S., Waisundara V.Y. Forestalling the Epidemics of Parkinson’s Disease Through Plant-Based Remedies. Front Nutr. 2018;5:95. doi: 10.3389/fnut.2018.00095.Pulikkalpura H., Kurup R., Mathew P.J., Baby S. Levodopa in Mucuna pruriens and its degradation. Sci Rep. 2015;5:11078. doi: 10.1038/srep11078.Pulikkalpura H., Kurup R., Mathew P.J., Baby S. Levodopa in Mucuna pruriens and its degradation. Sci Rep. 2015;5:11078. doi: 10.1038/srep11078.Bega D., Gonzalez-Latapi P., Zadikoff C., Simuni T. A review of the clinical evidence for complementary and alternative therapies in Parkinson’s disease. Curr Treat Options Neurol. 2014;16:314. doi: 10.1007/s11940-014-0314-5.Bega D., Gonzalez-Latapi P., Zadikoff C., Simuni T. A review of the clinical evidence for complementary and alternative therapies in Parkinson’s disease. Curr Treat Options Neurol. 2014;16:314. doi: 10.1007/s11940-014-0314-5.Ghaffari B.D., Kluger B. Mechanisms for alternative treatments in Parkinson’s disease: acupuncture, tai chi, and other treatments. Curr Neurol Neurosci Rep. 2014;14(6):451. doi: 10.1007/s11910-014-0451-y.Ghaffari B.D., Kluger B. Mechanisms for alternative treatments in Parkinson’s disease: acupuncture, tai chi, and other treatments. Curr Neurol Neurosci Rep. 2014;14(6):451. doi: 10.1007/s11910-014-0451-y.Maldonado R.G. Mucuna and Parkinson’s Disease: Treatment with Natural Levodopa. In: Yenisetti S.C. Parkinson’s Disease. Understanding Pathophysiology and Developing Therapeutic Strategies. 2018. doi: 10.5772/intechopen.74062.Maldonado R.G. Mucuna and Parkinson’s Disease: Treatment with Natural Levodopa. In: Yenisetti S.C. Parkinson’s Disease. Understanding Pathophysiology and Developing Therapeutic Strategies. 2018. doi: 10.5772/intechopen.74062.Ferguson C.C., Knol L.L., Halli-Tierney A., Ellis A.C. Dietary Supplement Use is High among Individuals with Parkinson Disease. South Med J. 2019;112(12):621–625. doi: 10.14423/SMJ.0000000000001041.Ferguson C.C., Knol L.L., Halli-Tierney A., Ellis A.C. Dietary Supplement Use is High among Individuals with Parkinson Disease. South Med J. 2019;112(12):621–625. doi: 10.14423/SMJ.0000000000001041.Manyam B.V., Sánchez-Ramos J.R. Traditional and complementary therapies in Parkinson’s disease. Adv Neurol. 1999;80:565–574. Available at: https://pubmed.ncbi.nlm.nih.gov/10410773/Manyam B.V., Sánchez-Ramos J.R. Traditional and complementary therapies in Parkinson’s disease. Adv Neurol. 1999;80:565–574. Available at: https://pubmed.ncbi.nlm.nih.gov/10410773/Singh R.H., Mishra L.C. Parkinson’s Disease (Kampa Vata). In: Mishra L.C. Scientific Basis for Ayurvedic Therapies. New York: CRC Press LLC; 2004. Available at: http://www.progenresearchlab.com/aricles/Scientific%20basis%20for%20Ayurvedic%20medicines-Book.pdf.Singh R.H., Mishra L.C. Parkinson’s Disease (Kampa Vata). In: Mishra L.C. Scientific Basis for Ayurvedic Therapies. New York: CRC Press LLC; 2004. Available at: http://www.progenresearchlab.com/aricles/Scientific%20basis%20for%20Ayurvedic%20medicines-Book.pdf.Суботялов М.А., Дружинин В.Ю. Аюрведа: источники и характеристика. М.: Философская книга; 2015. 272 с. Subotyalov M.A., Druzhinin V.Yu. Ayurveda: sources and characteristics. Moscow: Philosophical Book; 2015. 272 p. (In Russ.)Суботялов М.А., Дружинин В.Ю. Аюрведа: источники и характеристика. М.: Философская книга; 2015. 272 с. Subotyalov M.A., Druzhinin V.Yu. Ayurveda: sources and characteristics. Moscow: Philosophical Book; 2015. 272 p. (In Russ.)Singhal B., Lalkaka J., Sankhla C. Epidemiology and treatment of Parkinson’s disease in India. Parkinsonism Relat Disord. 2003;9(2):S105–S109. doi: 10.1016/s1353-8020(03)00024-5.Singhal B., Lalkaka J., Sankhla C. Epidemiology and treatment of Parkinson’s disease in India. Parkinsonism Relat Disord. 2003;9(2):S105–S109. doi: 10.1016/s1353-8020(03)00024-5.Ovallath S., Deepa P. The history of parkinsonism: descriptions in ancient Indian medical literature. Mov Disord. 2013;28(5):566–568. doi: 10.1002/mds.25420.Ovallath S., Deepa P. The history of parkinsonism: descriptions in ancient Indian medical literature. Mov Disord. 2013;28(5):566–568. doi: 10.1002/mds.25420.Hardebo J.E., Owman Ch. Barrier mechanisms for neurotransmitter monoamines and their precursors at the blood-brain interface. Annals of Neurology. 1980;8(1):1–31. doi: 10.1002/ana.410080102.Hardebo J.E., Owman Ch. Barrier mechanisms for neurotransmitter monoamines and their precursors at the blood-brain interface. Annals of Neurology. 1980;8(1):1–31. doi: 10.1002/ana.410080102.Ramya K.B., Thaakur S. Herbs containing L-Dopa: An update. Anc Sci Life. 2007;27(1):50–55. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330839/Ramya K.B., Thaakur S. Herbs containing L-Dopa: An update. Anc Sci Life. 2007;27(1):50–55. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330839/Soares A.R., Marchiosi R., Siqueira-Soares Rde C., Barbosa de Lima R., Dantas dos Santos W., Ferrarese-Filho O. The role of L-DOPA in plants. Plant Signal Behav. 2014;9(3):e28275. doi: 10.4161/psb.28275.Soares A.R., Marchiosi R., Siqueira-Soares Rde C., Barbosa de Lima R., Dantas dos Santos W., Ferrarese-Filho O. The role of L-DOPA in plants. Plant Signal Behav. 2014;9(3):e28275. doi: 10.4161/psb.28275.Katzenschlager R., Evans A., Manson A., Patsalos P.N., Ratnaraj N., Watt H. et al. Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry. 2004;75(12):1672–1677. doi: 10.1136/jnnp.2003.028761.Katzenschlager R., Evans A., Manson A., Patsalos P.N., Ratnaraj N., Watt H. et al. Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry. 2004;75(12):1672–1677. doi: 10.1136/jnnp.2003.028761.Lampariello L.R., Cortelazzo A., Guerranti R., Sticozzi C., Valacchi G. The Magic Velvet Bean of Mucuna pruriens. J Tradit Complement Med. 2012;2(4):331–339. doi: 10.1016/s2225-4110(16)30119-5.Lampariello L.R., Cortelazzo A., Guerranti R., Sticozzi C., Valacchi G. The Magic Velvet Bean of Mucuna pruriens. J Tradit Complement Med. 2012;2(4):331–339. doi: 10.1016/s2225-4110(16)30119-5.Singh S.K., Dhawan S.S., Lal R.K., Shanker K., Singh M. Biochemical characterization and spatio-temporal analysis of the putative L-DOPA pathway in Mucuna pruriens. Planta. 2018;248(5):1277–1287. doi: 10.1007/s00425-018-2978-7.Singh S.K., Dhawan S.S., Lal R.K., Shanker K., Singh M. Biochemical characterization and spatio-temporal analysis of the putative L-DOPA pathway in Mucuna pruriens. Planta. 2018;248(5):1277–1287. doi: 10.1007/s00425-018-2978-7.Cassani E., Cilia R., Laguna J., Barichella M., Contin M., Cereda E. et al. Mucuna pruriens for Parkinson’s disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile. J Neurol Sci. 2016;365:175–180. doi: 10.1016/j.jns.2016.04.001.Cassani E., Cilia R., Laguna J., Barichella M., Contin M., Cereda E. et al. Mucuna pruriens for Parkinson’s disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile. J Neurol Sci. 2016;365:175–180. doi: 10.1016/j.jns.2016.04.001.Fothergill-Misbah N., Maroo H., Cham M., Pezzoli G., Walker R., Cilia R. Could Mucuna pruriens be the answer to Parkinson’s disease management in sub-Saharan Africa and other low-income countries worldwide? Parkinsonism Relat Disord. 2020;73:3–7. doi: 10.1016/j.parkreldis.2020.03.002.Fothergill-Misbah N., Maroo H., Cham M., Pezzoli G., Walker R., Cilia R. Could Mucuna pruriens be the answer to Parkinson’s disease management in sub-Saharan Africa and other low-income countries worldwide? Parkinsonism Relat Disord. 2020;73:3–7. doi: 10.1016/j.parkreldis.2020.03.002.Rai S.N., Birla H., Singh S.S., Zahra W., Patil R.R., Jadhav J.P. et al. Mucuna pruriens Protects against MPTP Intoxicated Neuroinflammation in Parkinson’s Disease through NF-κB/pAKT Signaling Pathways. Front Aging Neurosci. 2017;9:421. doi: 10.3389/fnagi.2017.00421.Rai S.N., Birla H., Singh S.S., Zahra W., Patil R.R., Jadhav J.P. et al. Mucuna pruriens Protects against MPTP Intoxicated Neuroinflammation in Parkinson’s Disease through NF-κB/pAKT Signaling Pathways. Front Aging Neurosci. 2017;9:421. doi: 10.3389/fnagi.2017.00421.Johnson S.L., Park H.Y., DaSilva N.A., Vattem D.A., Ma H., Seeram N.P. Levodopa-Reduced Mucuna pruriens Seed Extract Shows Neuroprotective Effects against Parkinson’s Disease in Murine Microglia and Human Neuroblastoma Cells, Caenorhabditis elegans, and Drosophila melanogaster. Nutrients. 2018;10(9):E1139. doi: 10.3390/nu10091139.Johnson S.L., Park H.Y., DaSilva N.A., Vattem D.A., Ma H., Seeram N.P. Levodopa-Reduced Mucuna pruriens Seed Extract Shows Neuroprotective Effects against Parkinson’s Disease in Murine Microglia and Human Neuroblastoma Cells, Caenorhabditis elegans, and Drosophila melanogaster. Nutrients. 2018;10(9):E1139. doi: 10.3390/nu10091139.Pathak-Gandhi N., Vaidya A.D. Management of Parkinson’s disease in Ayurveda: Medicinal plants and adjuvant measures. J Ethnopharmacol. 2017;197:46–51. doi: 10.1016/j.jep.2016.08.020.Pathak-Gandhi N., Vaidya A.D. Management of Parkinson’s disease in Ayurveda: Medicinal plants and adjuvant measures. J Ethnopharmacol. 2017;197:46–51. doi: 10.1016/j.jep.2016.08.020.Manyam B.V., Dhanasekaran M., Hare T.A. Effect of antiparkinson drug HP-200 (Mucuna pruriens) on the central monoaminergic neurotransmitters. Phytother Res. 2004;18(2):97–101. doi: 10.1002/ptr.1407.Manyam B.V., Dhanasekaran M., Hare T.A. Effect of antiparkinson drug HP-200 (Mucuna pruriens) on the central monoaminergic neurotransmitters. Phytother Res. 2004;18(2):97–101. doi: 10.1002/ptr.1407.Manyam B.V., Dhanasekaran M., Hare T.A. Neuroprotective effects of the antiparkinson drug Mucuna pruriens. Phytother Res. 2004;18(9):706–712. doi: 10.1002/ptr.1514.Manyam B.V., Dhanasekaran M., Hare T.A. Neuroprotective effects of the antiparkinson drug Mucuna pruriens. Phytother Res. 2004;18(9):706–712. doi: 10.1002/ptr.1514.Kasture S., Pontis S., Pinna A., Schintu N., Spina L., Longoni R. et al. Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson’s disease. Neurotox Res. 2009;15(2):111–122. doi: 10.1007/s12640-009-9011-7.Kasture S., Pontis S., Pinna A., Schintu N., Spina L., Longoni R. et al. Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson’s disease. Neurotox Res. 2009;15(2):111–122. doi: 10.1007/s12640-009-9011-7.Poddighe S., De Rose F., Marotta R., Ruffilli R., Fanti M., Secci P.P. et al. Mucuna pruriens (Velvet bean) rescues motor, olfactory, mitochondrial and synaptic impairment in PINK1B9 Drosophila melanogaster genetic model of Parkinson’s disease. PLoS One. 2014;9(10):e110802. doi: 10.1371/journal.pone.0110802.Poddighe S., De Rose F., Marotta R., Ruffilli R., Fanti M., Secci P.P. et al. Mucuna pruriens (Velvet bean) rescues motor, olfactory, mitochondrial and synaptic impairment in PINK1B9 Drosophila melanogaster genetic model of Parkinson’s disease. PLoS One. 2014;9(10):e110802. doi: 10.1371/journal.pone.0110802.Lieu C.A., Kunselman A.R., Manyam B.V., Venkiteswaran K., Subramanian T. A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias. Parkinsonism Relat Disord. 2010;16(7):458–465. doi: 10.1016/j.parkreldis.2010.04.015.Lieu C.A., Kunselman A.R., Manyam B.V., Venkiteswaran K., Subramanian T. A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias. Parkinsonism Relat Disord. 2010;16(7):458–465. doi: 10.1016/j.parkreldis.2010.04.015.Lieu C.A., Venkiteswaran K., Gilmour T.P., Rao A.N., Petticoffer A.C., Gilbert E.V. et al. The Antiparkinsonian and Antidyskinetic Mechanisms of Mucuna pruriens in the MPTP-Treated Nonhuman Primate. Evid Based Complement Alternat Med. 2012;2012:840247. doi: 10.1155/2012/840247.Lieu C.A., Venkiteswaran K., Gilmour T.P., Rao A.N., Petticoffer A.C., Gilbert E.V. et al. The Antiparkinsonian and Antidyskinetic Mechanisms of Mucuna pruriens in the MPTP-Treated Nonhuman Primate. Evid Based Complement Alternat Med. 2012;2012:840247. doi: 10.1155/2012/840247.Yadav S.K., Prakash J., Chouhan S., Singh S.P. Mucuna pruriens seed extract reduces oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in paraquat-induced Parkinsonian mouse model. Neurochem Int. 2013;62(8):1039–1047. doi: 10.1016/j.neuint.2013.03.015.Yadav S.K., Prakash J., Chouhan S., Singh S.P. Mucuna pruriens seed extract reduces oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in paraquat-induced Parkinsonian mouse model. Neurochem Int. 2013;62(8):1039–1047. doi: 10.1016/j.neuint.2013.03.015.Yadav S.K., Prakash J., Chouhan S., Westfall S., Verma M., Singh T.D., Singh S.P. Comparison of the neuroprotective potential of Mucuna pruriens seed extract with estrogen in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice model. Neurochem Int. 2014;65:1–13. doi: 10.1016/j.neuint.2013.12.001.Yadav S.K., Prakash J., Chouhan S., Westfall S., Verma M., Singh T.D., Singh S.P. Comparison of the neuroprotective potential of Mucuna pruriens seed extract with estrogen in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice model. Neurochem Int. 2014;65:1–13. doi: 10.1016/j.neuint.2013.12.001.Yadav S.K., Rai S.N., Singh S.P. Mucuna pruriens reduces inducible nitric oxide synthase expression in Parkinsonian mice model. J Chem Neuroanat. 2017;80:1–10. doi: 10.1016/j.jchemneu.2016.11.009.Yadav S.K., Rai S.N., Singh S.P. Mucuna pruriens reduces inducible nitric oxide synthase expression in Parkinsonian mice model. J Chem Neuroanat. 2017;80:1–10. doi: 10.1016/j.jchemneu.2016.11.009.Martínez Leo E.E., Arana Argáez V.E., Acevedo Fernández J.J., Puc R.M., Segura Campos M.R. Effect of Enzymatic Digestion of Protein Derivatives Obtained from Mucuna pruriens L. on Production of Proinflammatory Mediators by BALB/c Mouse Macrophages. Appl Biochem Biotechnol. 2018;186(3):597–612. doi: 10.1007/s12010-018-2740-4.Martínez Leo E.E., Arana Argáez V.E., Acevedo Fernández J.J., Puc R.M., Segura Campos M.R. Effect of Enzymatic Digestion of Protein Derivatives Obtained from Mucuna pruriens L. on Production of Proinflammatory Mediators by BALB/c Mouse Macrophages. Appl Biochem Biotechnol. 2018;186(3):597–612. doi: 10.1007/s12010-018-2740-4.Baroli B., Loi E., Solari P., Kasture A., Moi L., Muroni P. et al. Evaluation of oxidative stress mechanisms and the effects of phytotherapic extracts on Parkinson’s disease Drosophila PINK1B9 model. FASEB J. 2019;33(10):11028–11034. doi: 10.1096/fj.201901010.Baroli B., Loi E., Solari P., Kasture A., Moi L., Muroni P. et al. Evaluation of oxidative stress mechanisms and the effects of phytotherapic extracts on Parkinson’s disease Drosophila PINK1B9 model. FASEB J. 2019;33(10):11028–11034. doi: 10.1096/fj.201901010.Rijntjes M. Knowing Your Beans in Parkinson’s Disease: A Critical Assessment of Current Knowledge about Different Beans and Their Compounds in the Treatment of Parkinson’s Disease and in Animal Models. Parkinsons Dis. 2019;2019:1349509. doi: 10.1155/2019/1349509.Rijntjes M. Knowing Your Beans in Parkinson’s Disease: A Critical Assessment of Current Knowledge about Different Beans and Their Compounds in the Treatment of Parkinson’s Disease and in Animal Models. Parkinsons Dis. 2019;2019:1349509. doi: 10.1155/2019/1349509.An alternative medicine treatment for Parkinson’s disease: results of a multicenter clinical trial. HP-200 in Parkinson’s Disease Study Group. J Altern Complement Med. 1995;1(3):249–255. doi: 10.1089/acm.1995.1.249.An alternative medicine treatment for Parkinson’s disease: results of a multicenter clinical trial. HP-200 in Parkinson’s Disease Study Group. J Altern Complement Med. 1995;1(3):249–255. doi: 10.1089/acm.1995.1.249.Nagashayana N., Sankarankutty P., Nampoothiri M.R., Mohan P.K., Mohanakumar K.P. Association of L-DOPA with recovery following Ayurveda medication in Parkinson’s disease. J Neurol Sci. 2000;176(2):124–127. doi: 10.1016/S0022-510X(00)00329-4.Nagashayana N., Sankarankutty P., Nampoothiri M.R., Mohan P.K., Mohanakumar K.P. Association of L-DOPA with recovery following Ayurveda medication in Parkinson’s disease. J Neurol Sci. 2000;176(2):124–127. doi: 10.1016/S0022-510X(00)00329-4.Cilia R., Laguna J., Cassani E., Cereda E., Pozzi N.G., Isaias I.U. et al. Mucuna pruriens in Parkinson disease: A double-blind, randomized, controlled, crossover study. Neurology. 2017;89(5):432–438. doi: 10.1212/WNL.0000000000004175.Cilia R., Laguna J., Cassani E., Cereda E., Pozzi N.G., Isaias I.U. et al. Mucuna pruriens in Parkinson disease: A double-blind, randomized, controlled, crossover study. Neurology. 2017;89(5):432–438. doi: 10.1212/WNL.0000000000004175.Cilia R., Laguna J., Cassani E., Cereda E., Raspini B., Barichella M., Pezzoli G. Daily intake of Mucuna pruriens in advanced Parkinson’s disease: A 16-week, noninferiority, randomized, crossover, pilot study. Parkinsonism Relat Disord. 2018;49:60–66. doi: 10.1016/j.parkreldis.2018.01.014.Cilia R., Laguna J., Cassani E., Cereda E., Raspini B., Barichella M., Pezzoli G. Daily intake of Mucuna pruriens in advanced Parkinson’s disease: A 16-week, noninferiority, randomized, crossover, pilot study. Parkinsonism Relat Disord. 2018;49:60–66. doi: 10.1016/j.parkreldis.2018.01.014.Radder D.L.M., Tiel Groenestege A.T., Boers I., Muilwijk E.W., Bloem B.R. Mucuna Pruriens Combined with Carbidopa in Parkinson’s Disease: A Case Report. J Parkinsons Dis. 2019;9(2):437–439. doi: 10.3233/JPD-181500.Radder D.L.M., Tiel Groenestege A.T., Boers I., Muilwijk E.W., Bloem B.R. Mucuna Pruriens Combined with Carbidopa in Parkinson’s Disease: A Case Report. J Parkinsons Dis. 2019;9(2):437–439. doi: 10.3233/JPD-181500.

The authors declare that there are no conflicts of interest present.